The integrated comprehension of lncRNA HOXA-AS3 implication on human diseases

Author(s): Qinfan Yao ¹ ^, ² ^, ³ ^, ⁴ , Cuili Wang ¹ ^, ² ^, ³ ^, ⁴ , Yucheng Wang ¹ ^, ² ^, ³ ^, ⁴ , Xiuyuan Zhang ¹ ^, ² ^, ³ ^, ⁴ , Hong Jiang ¹ ^, ² ^, ³ ^, ⁴ , Dajin Chen ¹ ^, ² ^, ³ ^, ⁴ ^,

Publication date (Electronic): 20 August 2022

Journal: Clinical & Translational Oncology

Publisher: Springer International Publishing

Keywords: HOXA-AS3, Long non-coding RNAs, Tumor promoter, Mechanism, Clinical applications

Read this article at

ScienceOpen Publisher PMC

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Long non-coding RNA (lncRNA) is a non-protein-coding RNA with a length of more than 200 nucleotides. Studies have shown that lncRNAs have vital impacts on various pathological processes and participate in the development of human diseases, usually through acting as competing endogenous RNAs to modulate miRNA expression and biological functions. lncRNA HOXA Cluster Antisense RNA 3 (HOXA-AS3) was a newly discovered lncRNA and has been demonstrated to be abnormally expressed in many diseases. Moreover, HOXA-AS3 expression was closely correlated with the clinicopathologic characteristics in cancer patients. In addition, HOXA-AS3 exhibited significant properties in regulating several biological processes, including cell proliferation, invasion, and migration. Furthermore, HOXA-AS3 has provided promising values in the diagnosis, prognosis, and therapeutic strategies of several diseases such as liver cancer, glioma, lung cancer, oral cancer, gastric cancer, and even atherosclerosis. In this review, we discuss the abnormal expression of HOXA-AS3 in several human disorders and some pathobiological processes and its clinical characteristics, followed by a summary of HOXA-AS3 functions, regulatory mechanisms, and clinical application potential.

Related collections

Most cited references 82

Record: found
Abstract: found
Article: found

Hallmarks of Cancer: The Next Generation

Douglas Hanahan, Robert A. Weinberg (2011)

The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions. Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metabolism and evading immune destruction. In addition to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment." Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer. Copyright © 2011 Elsevier Inc. All rights reserved.

0 comments Cited 11927 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Is Open Access

Mechanisms of long noncoding RNA function in development and disease

Sandra Schmitz, Phillip Grote, Bernhard Herrmann (2016)

Since decades it has been known that non-protein-coding RNAs have important cellular functions. Deep sequencing recently facilitated the discovery of thousands of novel transcripts, now classified as long noncoding RNAs (lncRNAs), in many vertebrate and invertebrate species. LncRNAs are involved in a wide range of cellular mechanisms, from almost all aspects of gene expression to protein translation and stability. Recent findings implicate lncRNAs as key players of cellular differentiation, cell lineage choice, organogenesis and tissue homeostasis. Moreover, lncRNAs are involved in pathological conditions such as cancer and cardiovascular disease, and therefore provide novel biomarkers and pharmaceutical targets. Here we discuss examples illustrating the versatility of lncRNAs in gene control, development and differentiation, as well as in human disease.

0 comments Cited 334 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma.

Ji-hang Yuan, Fu Sheng Yang, Fang Wang … (2014)

The role of TGF-β-induced epithelial-mesenchymal transition (EMT) in cancer cell dissemination is well established, but the involvement of lncRNAs in TGF-β signaling is still unknown. In this study, we observed that the lncRNA-activated by TGF-β (lncRNA-ATB) was upregulated in hepatocellular carcinoma (HCC) metastases and associated with poor prognosis. lncRNA-ATB upregulated ZEB1 and ZEB2 by competitively binding the miR-200 family and then induced EMT and invasion. In addition, lncRNA-ATB promoted organ colonization of disseminated tumor cells by binding IL-11 mRNA, autocrine induction of IL-11, and triggering STAT3 signaling. Globally, lncRNA-ATB promotes the invasion-metastasis cascade. Thus, these findings suggest that lncRNA-ATB, a mediator of TGF-β signaling, could predispose HCC patients to metastases and may serve as a potential target for antimetastatic therapies. Copyright © 2014 Elsevier Inc. All rights reserved.

0 comments Cited 295 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Hong Jiang: jianghong961106@zju.edu.cn

Dajin Chen:

ORCID: http://orcid.org/0000-0003-2822-1182

zju2001@zju.edu.cn

Journal

Journal ID (nlm-ta): Clin Transl Oncol

Journal ID (iso-abbrev): Clin Transl Oncol

Title: Clinical & Translational Oncology

Publisher: Springer International Publishing (Cham )

ISSN (Print): 1699-048X

ISSN (Electronic): 1699-3055

Publication date (Electronic): 20 August 2022

Publication date PMC-release: 20 August 2022

Publication date (Print): 2022

Volume: 24

Issue: 12

Pages: 2342-2350

Affiliations

[1 ]GRID grid.13402.34, ISNI 0000 0004 1759 700X, Kidney Disease Center, The First Affiliated Hospital, College of Medicine, , Zhejiang University, ; Qingchun Road 79, Hangzhou, 310003 China

[2 ]Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, Zhejiang Province China

[3 ]GRID grid.13402.34, ISNI 0000 0004 1759 700X, National Key Clinical Department of Kidney Diseases, Institute of Nephrology, , Zhejiang University, ; Hangzhou, China

[4 ]Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China

Author information

Dajin Chen http://orcid.org/0000-0003-2822-1182

Article

Publisher ID: 2920

DOI: 10.1007/s12094-022-02920-w

PMC ID: 9568475

PubMed ID: 35986859

SO-VID: 63cac83d-2234-43e8-8048-a1905a2f7625

License:

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

History

Date received : 14 June 2022

Date accepted : 1 August 2022

Funding

Funded by: FundRef http://dx.doi.org/10.13039/501100001809, National Natural Science Foundation of China;

Award ID: 81802085

Award Recipient : Dajin Chen

Funded by: the Natural Science Foundation of Zhejiang

Award ID: LY21H160033

Award Recipient : Dajin Chen

Custom metadata

issue-copyright-statement © The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO) 2022

ScienceOpen disciplines: Oncology & Radiotherapy

Keywords: hoxa-as3,long non-coding rnas,tumor promoter,mechanism,clinical applications

Data availability:

ScienceOpen disciplines: Oncology & Radiotherapy

Keywords: hoxa-as3, long non-coding rnas, tumor promoter, mechanism, clinical applications

The integrated comprehension of lncRNA HOXA-AS3 implication on human diseases

Read this article at

Abstract

Related collections

Genes & Diseases

Most cited references 82

Hallmarks of Cancer: The Next Generation

Mechanisms of long noncoding RNA function in development and disease

A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma.

Author and article information

Contributors

Journal

Affiliations

Author information

Article

History

Funding

Categories

Custom metadata

Comments

Comment on this article

Similar content 559

Cited by 4

Most referenced authors 1,182